Search the Newsreel

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?

Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron's cemiplimab (Libtayo) in patients with solid tumors. …

Woodline Partners (BHVN) discloses 5.1% beneficial stake in Biohaven

Woodline Partners LP has reported a beneficial ownership of 5.1% in Biohaven Ltd., amounting to 7,660,280 Common Shares. This ownership grants Woodline Partners sole voting and dispositive power over these shares, which are held through Woodline Master Fund LP and Woodline Spire Master Fund …

Renaissance Technologies LLC Acquires New Position in Biohaven Ltd. $BHVN

Renaissance Technologies LLC has acquired a new position in Biohaven Ltd. (NYSE:BHVN), purchasing 160,952 shares valued at approximately $1.36 million. This move comes as institutional investors collectively own 88.78% of Biohaven, with several major funds significantly increasing their stakes. Despite missing quarterly EPS expectations, …

Bank of America Securities Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)

Bank of America Securities has reiterated a Buy rating on Biohaven Ltd. (BHVN) with a price target of $11.00, despite the stock closing higher at $14.54. Analyst Dina Ramadane, who covers the Healthcare sector, has a 61.54% success rate on her recommendations. The broader …

Biohaven Pharma stock price target raised to $23 by RBC Capital

RBC Capital has raised its price target for Biohaven Pharma (NYSE:BHVN) to $23 from $22, maintaining an Outperform rating, following the company's second-quarter 2026 earnings report. The firm highlights potential opportunities in troriluzole and degrader data, estimating a more than $4 billion market by …

Biohaven (NYSE: BHVN) reports $267.8M H1 2026 loss and $267.9M in liquidity

Biohaven Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company, reported a net loss of $267.8 million for the first half of 2026, primarily due to $204.6 million in research and development expenses. The company maintains liquidity with $267.9 million in cash, cash equivalents, and marketable …

Biohaven (NYSE:BHVN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Biohaven (NYSE:BHVN) announced its quarterly earnings, reporting a loss of $0.78 per share, which missed analysts' consensus estimates by $0.02. Following the announcement, shares of Biohaven dropped 0.5% to $14.58. Despite the earnings miss, analyst sentiment for Biohaven remains a "Moderate Buy" with an …

Biohaven Ltd. $BHVN Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its stake in Biohaven Ltd. (NYSE:BHVN) by 52.5% in Q1, now owning 202,975 shares valued at $1.72 million. Other institutional investors also significantly increased their holdings, with hedge funds and institutional investors collectively owning 88.78% of the stock. …

Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results

First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed, Phase 3 trial underway Positive clinical biomarker and patient data presented from Biohaven's extracellular degrader platform demonstrated deep, rapid, selective lowering of disease-driving …

Biohaven Ltd. Announces Q2 2026 Financial Results Highlighting Reduced Losses and R&D Spending

Biohaven Ltd. has filed its Q2 2026 financial report, revealing continued operating losses but also a reduction in research and development spending compared to the previous year. This report covers the three- and six-month periods ending June 30, 2026. The full details are available …

Biohaven earnings set to show cash burn ahead of epilepsy data

Biohaven Pharmaceutical Holding Co Ltd is expected to report its second-quarter earnings, with analysts forecasting a narrower loss of 75 cents per share. Investors will be closely watching the company's cash burn rate and updates on its epilepsy drug candidate, opakalim, which has topline …

Biohaven Ltd (BHVN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Understanding Momentum Shifts in (BHVN)

This article analyzes Biohaven Ltd. (BHVN) stock, highlighting a potential shift where strong near-term sentiment might challenge persistent mid and long-term weakness. It identifies resistance testing and outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones for …

Biohaven Ltd. Announces Appointment of John Yetimoglu to Board of Directors, Effective August 6, 2026

Biohaven Ltd. has announced the appointment of John Yetimoglu to its Board of Directors and as a member of the Nominating and Governance Committee, effective August 6, 2026. Mr. Yetimoglu, founder and CIO of Infinitum, brings expertise in semiconductors, videogaming, and AI application platforms. …

Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors

Biohaven Ltd. (NYSE: BHVN) has appointed John Yetimoglu, founder and CIO of Infinitum and a board director at Groq, to its Board of Directors. Yetimoglu brings extensive experience in frontier AI and technology investing, which Biohaven anticipates will strengthen its strategic oversight as it …

Biohaven Ltd. (BHVN) Stock Price, News, Quote & History

This Yahoo Finance page provides detailed stock information for Biohaven Ltd. (BHVN), including its current stock price, historical data, key events, and financial metrics. The company, a biopharmaceutical firm, focuses on treatments for immunology, neuroscience, and oncology, with several drug candidates in various clinical …

Biohaven (BHVN) Adds AI Expertise To Its Board, Is The Valuation Gap Too Wide?

Biohaven (BHVN) recently appointed John Yetimoglu, an AI-focused investment leader, to its Board, signaling a stronger push into data-driven drug discovery. Despite recent stock volatility, a Discounted Cash Flow (DCF) model suggests Biohaven is significantly undervalued at $13.63, with a fair value estimate of …

Biohaven Adds Technology Investor John Yetimoglu to Board as AI Strategy Advances

Biohaven Ltd. (NYSE: BHVN) has appointed technology investor John Yetimoglu to its Board of Directors to bolster its artificial intelligence and computational technologies strategy in drug discovery and development. Yetimoglu, founder of Infinitum and an early investor in Groq, brings extensive experience in emerging …

Biohaven (BHVN) Expected to Release Quarterly Earnings on Monday

Defilade Capital Management L.P. Buys Shares of 315,944 Biohaven Ltd. $BHVN

Biohaven Ltd. $BHVN Shares Bought by Janus Henderson Group PLC

Biohaven Pharma earnings on deck amid epilepsy trial scrutiny

Biohaven Pharmaceutical Holding Co. is set to report second-quarter results, with analysts anticipating a narrower loss per share. Investors will be closely watching for updates on the company's cash runway and the timeline for pivotal Phase 2/3 epilepsy trial results for its experimental drug, …

Biohaven Insiders Added US$33.1m Of Stock To Their Holdings

This article discusses recent insider purchases at Biohaven Pharmaceutical Holding Company. Insiders bought US$33.1 million worth of stock, suggesting confidence in the company's future despite a recent share price decline. The purchases come after the company's acquisition of a migraine drug by Pfizer, which …

Biohaven Ltd (BHVN) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Biohaven Ltd (BHVN), covering operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flow and Biohaven's specific cash flow figures for operating, investing, financing, and …

Biohaven (BHVN) Following Its Court Win Still Looks Cheap Against Fair Value

Biohaven (BHVN) recently won a federal jury case related to misappropriated trade secrets, yet its share price has seen a short-term decline despite strong 90-day and year-to-date gains. A Discounted Cash Flow (DCF) model estimates Biohaven's fair value at $61.24, significantly higher than its …

Biohaven and Yale win $4M verdict in trade secret case

A federal jury awarded Biohaven Ltd. and Yale University $4 million in a trade secret misappropriation case against Avilar Therapeutics, Inc. and RA Capital Management GP, LLC. The jury found that Avilar and RA Capital willfully and maliciously misappropriated a Yale trade secret related …

Yale, Biohaven Win $4M In Biotech Trade Secret Trial

A Delaware federal jury has awarded Yale University and Biohaven Therapeutics $4 million in a biotech trade secret trial. The verdict found that venture capital firm RA Capital Management GP breached a confidentiality agreement and, along with Avilar Therapeutics, misappropriated a Yale-developed trade secret …

Yale, Biohaven Win $4 Million Verdict Over Drug-Development Tech

Yale University and Biohaven Therapeutics Ltd. were jointly awarded $4 million in a Delaware trial. The verdict found Avilar Therapeutics Inc. and RA Capital Management GP LLC liable for misappropriating Yale's "MODA" drug-development trade secret and for breaching a confidentiality agreement. The jury specifically …

Biohaven Awarded $1 Million Over Alleged Trade Secret Violations by Avilar Therapeutics, RA Capital Management

Biohaven (BHVN) said Monday that a federal jury has awarded it $1 million in damages over an alleged PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. …

Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million

A federal jury found Avilar Therapeutics and RA Capital Management GP, LLC guilty of willfully and maliciously misappropriating a trade secret developed at Yale University related to its "MODA" targeted protein degradation platform. RA Capital was also found to have breached a confidentiality agreement …

How Biohaven’s (BHVN) Trade Secret Verdict Shapes Its Intellectual Property Defense Strategy

Biohaven recently won a US$1,000,000 trade secret lawsuit, reinforcing its commitment to protecting intellectual property. While this win strengthens the narrative around IP quality, it doesn't change the company's core investment risks, which include clinical outcomes, funding needs, and potential shareholder dilution. Biohaven remains …

Biohaven Ltd (BHVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Biohaven Ltd (BHVN) stock, focusing on various indicators and moving averages. It presents a summary of buy, neutral, and sell signals derived from tools such as MACD, RSI, and different moving average periods. The analysis concludes with …

BHVN|Biohaven Ltd|Price:14.320|Chg%:-0.320

This article provides a detailed financial overview of Biohaven Ltd (BHVN), including key financial indicators, income statements, balance sheets, and cash flow statements for various quarters and fiscal years. It highlights the company's latest earnings, revenue forecasts, and analyst ratings, presenting a comprehensive data …